MX6A.F GRAND PHARM. GRP. HD-01
- Market cap
- EUR 1.71B
- P/E
- 11.8x
- P/B
- 0.84x
- ROE
- 7.3%
- Dividend yield
- 3.98%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MX6A.F undervalued?
Graham numberMX6A.F trades 33.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GRAND PHARM. GRP. HD-01 fundamental analysis
No fundamental analysis for GRAND PHARM. GRP. HD-01 yet.
GRAND PHARM. GRP. HD-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GRAND PHARM. GRP. HD-01
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series …
Full company profileGRAND PHARM. GRP. HD-01 financial statements
GRAND PHARM. GRP. HD-01 annual financial statements (HKD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 8.60B | 9.56B | 10.5B | 11.6B | 12.3B |
| Gross Profit | 5.25B | 5.95B | 6.52B | 6.74B | 6.78B |
| Operating Income | 2.01B | 2.68B | 2.82B | 2.17B | 1.68B |
| EBITDA | - | 3.05B | 2.94B | 3.54B | 2.24B |
| Net Income | 2.40B | 2.08B | 1.88B | 2.47B | 1.24B |
| EPS | 0.68 | 0.59 | 0.54 | 0.70 | 0.35 |
| Balance Sheet | |||||
| Total Assets | 21.1B | 22.4B | 22.5B | 25.0B | 27.2B |
| Total Liabilities | 7.61B | 8.16B | 7.24B | 8.47B | 9.99B |
| Shareholders' Equity | 13.4B | 14.1B | 15.2B | 16.5B | 17.0B |
| Cash & Short-term Investments | 1.75B | 1.44B | 1.34B | 1.34B | 1.14B |
| Cash Flow | |||||
| Operating Cash Flow | 2.01B | 1.84B | 2.42B | 1.90B | 1.65B |
| Capital Expenditure | 536M | 1.09B | 498M | 622M | 1.52B |
| Free Cash Flow | 1.47B | 758M | 1.93B | 1.28B | 127M |
| Ratios | |||||
| ROE | 17.9% | 14.7% | 12.4% | 15.0% | 7.3% |
| ROA | 11.4% | 9.3% | 8.3% | 9.9% | 4.6% |
| Net Profit Margin | 27.9% | 21.7% | 17.9% | 21.2% | 10.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GRAND PHARM. GRP. HD-01 dividends
- Dividend yield
- 3.98%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 73.4%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | HKD 910M | 0.26 | 73.4% |
| 2024 | HKD 910M | 0.26 | 36.9% |
| 2023 | HKD 497M | 0.14 | 26.4% |
| 2022 | HKD 390M | 0.11 | 18.8% |
| 2021 | HKD 390M | 0.11 | 16.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns GRAND PHARM. GRP. HD-01
- Insiders 56.39%
- Institutions 17.08%
- Public & others 26.53%
- Shares outstanding 3.50B
- Free float 1.26B
GRAND PHARM. GRP. HD-01 company profile
- Company name
- GRAND PHARM. GRP. HD-01
- Ticker
- MX6A.F
- ISIN
- BMG210A71016
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 12,326
- Fiscal year end
- December
- Address
- The Center, Central, Hong Kong
- Website
- grandpharm.com
About GRAND PHARM. GRP. HD-01
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine, and health food products. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
GRAND PHARM. GRP. HD-01 management
7- Dr. Weikun TangExecutive Chairman · born 1986
- Mr. Chao ZhouCEO & Executive Director · born 1990
- Ms. Chit Yee LamExecutive Director · born 1966
- Liu HuInvestor Relations Director
- Mr. Tin Chung Foo CPA (Aust.), HKICPACompany Secretary · born 1969
- Mr. Xiaofeng ShiChairman of Grand Pharm (China) · born 1967
- Xiaojie ChenVice President